Searching for biomarkers of CDKL5 disorder: early-onset visual impairment in CDKL5 mutant mice.

Hum Mol Genet

Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence, Area San Salvi - Pad. 26, 50135 Florence, Italy.

Published: June 2017

CDKL5 disorder is a neurodevelopmental disorder still without a cure. Murine models of CDKL5 disorder have been recently generated raising the possibility of preclinical testing of treatments. However, unbiased, quantitative biomarkers of high translational value to monitor brain function are still missing. Moreover, the analysis of treatment is hindered by the challenge of repeatedly and non-invasively testing neuronal function. We analyzed the development of visual responses in a mouse model of CDKL5 disorder to introduce visually evoked responses as a quantitative method to assess cortical circuit function. Cortical visual responses were assessed in CDKL5 null male mice, heterozygous females, and their respective control wild-type littermates by repeated transcranial optical imaging from P27 until P32. No difference between wild-type and mutant mice was present at P25-P26 whereas defective responses appeared from P27-P28 both in heterozygous and homozygous CDKL5 mutant mice. These results were confirmed by visually evoked potentials (VEPs) recorded from the visual cortex of a different cohort. The previously imaged mice were also analyzed at P60-80 using VEPs, revealing a persistent reduction of response amplitude, reduced visual acuity and defective contrast function. The level of adult impairment was significantly correlated with the reduction in visual responses observed during development. Support vector machine showed that multi-dimensional visual assessment can be used to automatically classify mutant and wt mice with high reliability. Thus, monitoring visual responses represents a promising biomarker for preclinical and clinical studies on CDKL5 disorder.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5458338PMC
http://dx.doi.org/10.1093/hmg/ddx119DOI Listing

Publication Analysis

Top Keywords

cdkl5 disorder
20
mutant mice
16
visual responses
16
cdkl5
8
visual
8
cdkl5 mutant
8
visually evoked
8
disorder
6
mice
6
responses
6

Similar Publications

Independent genetic strategies define the scope and limits of CDKL5 deficiency disorder reversal.

Cell Rep Med

January 2025

Department of Genetics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19102, USA; Department of Neuroscience, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19102, USA; The Epigenetics Institute, University of Pennsylvania, Philadelphia, PA 19102, USA. Electronic address:

Cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) is a neurodevelopmental syndrome caused by mutations in the X-linked CDKL5 gene. The early onset of CDD suggests that CDKL5 is essential during development, but post-developmental re-expression rescues multiple CDD-related phenotypes in hemizygous male mice. Since most patients are heterozygous females, studies in clinically relevant female models are essential.

View Article and Find Full Text PDF

Ganaxolone: A Review in Epileptic Seizures Associated with Cyclin-Dependent Kinase-Like 5 Deficiency Disorder.

Paediatr Drugs

January 2025

Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.

Oral ganaxolone (ZTALMY), a synthetic analogue of the endogenous neuroactive steroid allopregnanolone, acts as a positive allosteric modulator of synaptic and extra-synaptic γ-aminobutyric acid (GABA) type A receptor function in the CNS. In the EU and the UK, it is approved for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients aged 2-17 years. In a multinational phase III study (Marigold), 17 weeks' therapy with adjunctive ganaxolone, administered orally three times daily with food, significantly reduced 28-day major motor seizure frequency from baseline versus placebo in patients aged 2-19 years with CDD-associated refractory epilepsy.

View Article and Find Full Text PDF

Engineered tRNAs efficiently suppress CDKL5 premature termination codons.

Sci Rep

December 2024

Department of Medical Biotechnology and Translational Medicine, University of Milan, Segrate (Milan), 20054, Italy.

Article Synopsis
  • The CDKL5 deficiency disorder (CDD) is a severe neurodevelopmental condition with symptoms including early epilepsy, intellectual disabilities, and motor/visual dysfunction, caused by mutations in the CDKL5 gene.
  • Currently, there is no cure for CDD; treatments focus on managing seizures, though some genetic therapies show promise in addressing the disorder's root causes.
  • Recent studies using Anticodon-edited tRNAs (ACE-tRNAs) have shown potential in restoring full-length CDKL5 protein synthesis, opening up possibilities for effective new treatments for patients with nonsense mutations.
View Article and Find Full Text PDF

Measuring the Burden of Epilepsy Hospitalizations in CDKL5 Deficiency Disorder.

Pediatr Neurol

February 2025

The Kids Research Institute Australia, The University of Western Australia, Northern Entrance, Western Australia, Australia. Electronic address:

Background: Information on the hospital service use among individuals with CDKL5 Deficiency Disorder, an ultrarare developmental epileptic encephalopathy, is limited, evidence of which could assist with service planning. Therefore, using baseline and longitudinal data on 379 genetically verified individuals in the International CDKL5 Disorder Database, we aimed to investigate rates of seizure-related and other hospitalizations and associated length of stay in this cohort.

Methods: Outcome variables were lifetime count of family-reported hospitalizations and average length of stay both for seizure- (management and/or investigative) and non-seizure-related causes.

View Article and Find Full Text PDF

Purpose: CDKL5 deficiency disorder (CDD) is a developmental and epileptic encephalopathy with multisystemic comorbidities. Cardiovascular involvement in CDD was shown in animal models but is yet poorly described in CDD cohorts.

Methods: We identified 38 individuals with genetically confirmed CDD through the Cleveland Clinic CDD specialty clinic and matched 190 individuals with non-genetic epilepsy to them as a comparison group.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!